Drug Profile
R-verapramil - Center Laboratories
Alternative Names: (R)-verapamil - Center Laboratories; Arverapamil - Center Laboratories; CS 02Latest Information Update: 02 Dec 2020
Price :
$50
*
At a glance
- Originator Center Laboratories
- Class Analgesics; Antiarrhythmics; Antihyperglycaemics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
- Mechanism of Action Calcium channel antagonists; Melatonin MT1 receptor modulators; Serotonin 2B receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cluster headache; Type 2 diabetes mellitus
Most Recent Events
- 10 Jul 2020 R-Verapamil - Center Laboratories is available for licensing as of 10 Jul 2020. https://www.centerventures.com.tw/en/industrial/company/18
- 10 Jul 2020 Efficacy data from a phase II trial in Type 2 diabetes mellitus released by Center Laboratories
- 08 Jun 2020 Center Laboratories completes a phase-II clinical trials in Type-2 diabetes mellitus (Combination therapy) in Taiwan and USA (PO) (NCT03317028)